Assessing Risk Of Disease Progression In First-Line Mcrc Therapy

Assessing risk of disease progression in first-line mCRC therapy

Second-Line Therapy for RAS Wild-Type mCRC

Dr. Bordonaro on First-Line Treatment Options for mCRC

Dr. Bordonaro on First-Line Treatment Options for mCRC

Targeted Oncology

Debate: Is there an optimal sequence for first-line therapy in mCRC? - Yes

Debate: Is there an optimal sequence for first-line therapy in mCRC? - No

Deciding Second-Line Treatment for mCRC

mCRC: Factors to Consider for First-Line Therapy

Targeted Oncology

Remaining questions for the treatment of patients with MSI/dMMR mCRC with immunotherapy

Second-Line Therapy for RAS Wild-Type mCRC

Unanswered questions regarding the use of first-line therapy in mCRC

Molecular Testing and First-Line Therapy in mCRC

Targeted Oncology

First- and Second-Line Treatment for mCRC in Specific Populations

First-Line Treatment of Poor-Risk Metastatic Renal Cell Carcinoma

mCRC: Therapeutic Approach at Progression

Targeted Oncology

Colorectal Cancer: Sequencing and Therapeutic Approaches in First- and Next-Line Treatment

Limitations of post-hoc analysis in guideline development for colorectal cancer

Optimizing Therapy in HER2+ Disease with Dr. Reshma Mahtani

Total Health | Oncology

Initial Management of Metastatic CRC in 2019

Expert Report on panitumumab for first line treatment of RAS wild type mCRC from ASCO 2022

European Society for Medical Oncology (ESMO)